Can vaccination be used as a mild inflammatory challenge to study sickness behavior and cytokine responses?

Why a vaccine can stand in for an infection

An inflammatory challenge is simply a controlled way of nudging the immune system and then measuring what happens. A vaccine does this gently: it provokes an acute cytokine response, including the inflammatory signal interleukin-6 (IL-6), but the response is milder than what a real infection or a stronger stimulus like LPS produces [1]. That matters because the point is to study inflammation's effects on behavior, not the effects of feeling sick.

The typhoid vaccine was chosen deliberately for this reason. Its cytokine response is described as closer in magnitude to what is seen in chronic disease and some psychiatric conditions than the responses triggered by stronger stimuli, which resemble acute infection [1]. In practical terms, a vaccine gives researchers an inflammation signal in a range that may be more relevant to stress and depression than to a bout of flu.

What researchers actually observe after vaccination

The most direct evidence comes from the influenza vaccine. In that study, greater rises in IL-6 after vaccination were associated with changes in automatic social behavior—how people spontaneously approached or withdrew from a social support figure and from strangers [2]. The behavior measured was automatic, not a deliberate choice, so the finding is about subtle shifts in social responding rather than overt illness behavior.

The typhoid vaccine work points in a similar direction. It examines links between inflammation, social behavior, and cytokine levels, and the author suggests that as the inflammatory response grows, neural sensitivity and subconscious social processes may grow with it [1]. One interpretation offered is that inflammation may not push people toward seeking new social contacts, but rather toward drawing closer to people they already feel bonded to—though the author explicitly notes this needs direct testing [1].

Why the mildness of the response is the point

A stronger challenge creates a problem: people feel sick, and sickness itself can slow thinking and change behavior. Because the vaccine response is milder, participants experience fewer sickness symptoms, so those symptoms don't confound cognitive testing [1]. That is what makes vaccination attractive for studies that need participants alert enough to complete behavioral and cognitive tasks.

The same logic appears in work on sleepiness after COVID-19 vaccination, which hypothesizes that pro-inflammatory cytokines affect orexinergic neurons—brain cells involved in wakefulness—and links this to sickness behavior [3]. That is a hypothesis about a mechanism, not a demonstrated pathway, but it illustrates the kind of question a mild vaccine challenge makes tractable: how cytokine signals might reach the brain and produce something as ordinary as drowsiness.

What a vaccine challenge can and cannot tell us

Vaccination is not a universal stand-in for immune challenge. Much of the mechanistic detail about how sickness behavior unfolds—such as the sequence in which microglia and astrocytes begin expressing inflammatory cytokines after a systemic challenge, with cytokine mRNA rising within two hours and tracking active sickness behavior—comes from LPS studies, not vaccines [4]. Similarly, work showing that the cytokine IL-4 can modify LPS-induced social withdrawal in rats relies on central injections and LPS, a different and stronger paradigm [5].

So the honest answer is that vaccination is a useful mild challenge for studying cytokine responses and subtle social or cognitive changes in people, while stronger stimuli remain the tool for dissecting cellular mechanisms. The two approaches answer different questions, and the vaccine's value lies precisely in being gentle enough to separate inflammation's effects from the experience of being ill [1][2].

Sources used in this answer

Related research questions